Alexandria is a life-science office REIT trading at 5.9x operating cash flow with a 7.2% dividend and 25% analyst upside, but revenue is down 11%, the stock is 50% off its high in a downtrend, and 53% of NOI comes from a concentrated tenant base.
Thesis pillars
- Tenant Concentration Cliff↑Improving
- Cash Flow Value Discount→Stable
- Declining Revenue Weak Growth→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Jan 26, 2026
Alexandria Real Estate Equities (ARE) Stock Analysis
Recovery setup
Real Estate · REIT - Office
Sell if holding. At $46.00, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science.
Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling approximately 39.4 million RSF, concentrated in Greater Boston, San Francisco Bay Area, San Diego, and five other U.S. innovation cluster markets. The company earns... Read more
Sell if holding. At $46.00, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science. Chart setup: Death cross but MACD improving, RSI 61. Score 4.4/10, high confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and reit tenant cliff hard block. Suitability: speculative.
About Alexandria Real Estate Equities
About Alexandria Real Estate Equities
Alexandria Real Estate Equities owns 35.9 million RSF of operating life science laboratory properties concentrated in seven U.S. innovation cluster markets, including Greater Boston, San Francisco Bay Area, and San Diego. At December 31, 2025, portfolio occupancy was 90.9%, investment-grade or publicly traded large cap tenants contributed 53% of annual rental revenue, and 3.5 million RSF of Class A/A+ properties were under construction. The company reported a total market capitalization of $20.75 billion.
Alexandria earns rental revenue primarily through triple-net leases, with approximately 92% of leases (on an annual rental revenue basis) structured as NNN arrangements that pass substantially all taxes, insurance, utilities, and operating expenses to tenants. Roughly 97% of leases contained annual rent escalations of approximately 3%, either fixed or indexed to CPI, providing contractual growth in base rent. The tenant base spans multinational pharmaceutical companies, biotechnology firms, life science product and device companies, academic research institutions, U.S. government research agencies, and venture capital firms. Properties are concentrated in seven geographic segments — Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City — primarily within Megacampus environments designed for laboratory and collaborative research use. Competitors for investment opportunities include other REITs, insurance companies, pension funds, private equity entities, and foreign investors.
Show full overview
Alexandria's portfolio consists entirely of life science laboratory properties, and the 10-K explicitly flags dependence on the health of the life science industry as a material risk. Policy changes at the FDA, NIH, and SEC — or reductions in government spending and research funding — could materially affect tenants' ability to secure capital for research and development or to commercialize products, in turn impairing their ability to make rental payments. A partial or complete government shutdown could delay commercialization timelines or reduce R&D funding, exposing the portfolio to tenant financial stress beyond typical real estate credit risk.
See also: Real Estate · REIT - Office
From Alexandria Real Estate Equities's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Oct 26, 2026Recent Developments — Alexandria Real Estate Equities
Latest news
- NEWS Alexandria Real Estate Equities, Inc. Reports 3Q26 and YTD 3Q26 Net Loss per Share - Diluted of $3.74 and $2.06, respect — Morningstar Oct 26, 2026 negative
- NEWS Caught Out By Alexandria Real Estate? What The Bears Saw - Simply Wall Street — Simply Wall Street Oct 24, 2026 negative
- NEWS Alexandria Real Estate Equities Inc. stock underperforms Thursday when compared to competitors despite daily gains - Mar — MarketWatch Oct 22, 2026 negative
- NEWS Alexandria's Q3 Earnings Preview: Is ARE Stock a Portfolio Must-Have? - Yahoo Finance — Yahoo Finance Oct 22, 2026 neutral
- NEWS Analysts’ Opinions Are Mixed on These Real Estate Stocks: Alexandria Equities (ARE) and AGNC Investment (AGNC) - The Glo — The Globe and Mail Oct 22, 2026 neutral
Latest item Oct 26, 2026 · Generated 2026-11-05T12:04:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHPropertylife science10-K Item 1A: 'We are dependent on the health of the life science industry, and changes within this industry...may adversely impact their ability to make rental payments to us'
- HIGHTenantinvestment-grade or publicly traded large cap tenants53%10-K Item 1: 'Investment-grade or publicly traded large cap tenants represented 53% of our total annual rental revenue in effect as of December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -10.8% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $46.00, A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $42.78. Score 4.4/10, high confidence.
Analyst target $43.44 reached (−5.6% from $46.00); no take-profit level is published. Prior stop was $42.78. Stop-loss: $42.78.
REIT tenant concentration cliff: 53% of NOI from investment-grade or publicly traded large cap tenants (≥40% threshold). Single-tenant churn risk dominates spot FFO.; Concentration risk — Property Type: life science; Concentration risk — Tenant: investment-grade or publicly traded large cap tenants (53.0%).
Alexandria Real Estate Equities trades at a P/E of N/A (forward -48.9). TrendMatrix value score: 5.2/10. Verdict: Sell.
24 analysts rate ARE, with a consensus score of 2.6/5. 14 analysts publish price targets averaging $50.
What does Alexandria Real Estate Equities do?Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling...
Alexandria Real Estate Equities owns and operates 340 life science REIT properties in North America totaling approximately 39.4 million RSF, concentrated in Greater Boston, San Francisco Bay Area, San Diego, and five other U.S. innovation cluster markets. The company earns rental income under primarily triple-net leases with pharmaceutical, biotech, and research institution tenants, with 90.9% portfolio occupancy and 53% of rental revenue from investment-grade or publicly traded large cap tenants as of December 31, 2025.